Finance Watch: Bausch + Lomb Completes Split From Bausch Health Via IPO

PepGen Went Public On 5 May As Well

Public Company Edition: Bausch remains the majority shareholder, but B+L is a separate operating company. Also, Rezolute raises $130m in dual financings and BridgeBio outlines job cuts and will out-license assets to conserve cash.

Finance Watch Public Company — • Source: Alamy

Bausch + Lomb, Corporation finally completed its long-anticipated split from Bausch Health Companies Inc. via an initial public offering on 5 May that grossed $630m from the sale of 35 million shares at $18 each, but Bausch Health continues to be the majority shareholder in the eye care company.

The offering priced well below the $21 to $24 range that Bausch + Lomb proposed in a 28 April filing...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Q2 Korea Biotech Roundup: Licensing Deals End, Trials Progress, IPOs Recover

15 Jul 2025

• By Jung Won Shin

Aside from several sizable global out-licensing deals, South Korean bioventures saw a cancellation of other alliances, updated their pipelines with losses and gains and reported clinical trial progress in the second quarter, while domestic IPO sentiment also improved.

Bayer’s Kerendia Gains Blockbuster Indication For Heart Failure

14 Jul 2025

• By Joseph Haas

New US approval in heart failure with preserved or mildly reduced ejection fraction should add to Kerendia’s earning power on top of chronic kidney disease indication.

Takeda Prepares Ground For Oveporexton In Narcolepsy

14 Jul 2025

• By Alaric DeArment

The drugmaker announced positive results from two Phase III trials for the drug in narcolepsy type 1 that analysts said bode well for the OX2R agonist class as a whole.